中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2010年
27期
24-26
,共3页
许春森%林舜国%韩晖%韩忠华
許春森%林舜國%韓暉%韓忠華
허춘삼%림순국%한휘%한충화
乳腺肿瘤%受体,雌激素%预后%临床特征
乳腺腫瘤%受體,雌激素%預後%臨床特徵
유선종류%수체,자격소%예후%림상특정
Breast neoplasms%Receptors,estrogen%Prognosis%Clinical characteristics
目的 分析三阴性乳腺癌的临床病理学特征及其预后.方法 回顾性分析2005年1月至2007年6月570例乳腺癌患者的临床资料,其中雌激素受体(ER)、孕激素受体(PR)、HER-2均阴性(ER-/PR-/HER-2-)113例(观察组)和ER-/PR-/HER-2+48例(对照组).比较两组的临床病理学特征、复发和生存情况.结果 观察组中位年龄46岁,13.3%(15/113)的患者有乳腺癌或卵巢癌家族史,86.7%(98/113)的病理类型为浸润性导管癌,31.0%(35/113)的患者合并腋窝淋巴结转移,58.4%(66/113)的患者有p53表达,与对照组比较差异无统计学意义(P＞0.05).中位随访时间24个月,失访5例,10例(9.3%,10/108)出现复发转移(其中肝、肺转移6例,骨转移3例,脑转移1例),其中8例(7.4%,8/108)死于远处转移,2年生存率96.2%,与对照组比较差异无统计学意义(P＞0.05).结论 三阴性乳腺癌发病率较高,和ER-/PR-/HER-2+亚型乳腺癌的临床病理学特征相似,预后相仿.
目的 分析三陰性乳腺癌的臨床病理學特徵及其預後.方法 迴顧性分析2005年1月至2007年6月570例乳腺癌患者的臨床資料,其中雌激素受體(ER)、孕激素受體(PR)、HER-2均陰性(ER-/PR-/HER-2-)113例(觀察組)和ER-/PR-/HER-2+48例(對照組).比較兩組的臨床病理學特徵、複髮和生存情況.結果 觀察組中位年齡46歲,13.3%(15/113)的患者有乳腺癌或卵巢癌傢族史,86.7%(98/113)的病理類型為浸潤性導管癌,31.0%(35/113)的患者閤併腋窩淋巴結轉移,58.4%(66/113)的患者有p53錶達,與對照組比較差異無統計學意義(P＞0.05).中位隨訪時間24箇月,失訪5例,10例(9.3%,10/108)齣現複髮轉移(其中肝、肺轉移6例,骨轉移3例,腦轉移1例),其中8例(7.4%,8/108)死于遠處轉移,2年生存率96.2%,與對照組比較差異無統計學意義(P＞0.05).結論 三陰性乳腺癌髮病率較高,和ER-/PR-/HER-2+亞型乳腺癌的臨床病理學特徵相似,預後相倣.
목적 분석삼음성유선암적림상병이학특정급기예후.방법 회고성분석2005년1월지2007년6월570례유선암환자적림상자료,기중자격소수체(ER)、잉격소수체(PR)、HER-2균음성(ER-/PR-/HER-2-)113례(관찰조)화ER-/PR-/HER-2+48례(대조조).비교량조적림상병이학특정、복발화생존정황.결과 관찰조중위년령46세,13.3%(15/113)적환자유유선암혹란소암가족사,86.7%(98/113)적병리류형위침윤성도관암,31.0%(35/113)적환자합병액와림파결전이,58.4%(66/113)적환자유p53표체,여대조조비교차이무통계학의의(P＞0.05).중위수방시간24개월,실방5례,10례(9.3%,10/108)출현복발전이(기중간、폐전이6례,골전이3례,뇌전이1례),기중8례(7.4%,8/108)사우원처전이,2년생존솔96.2%,여대조조비교차이무통계학의의(P＞0.05).결론 삼음성유선암발병솔교고,화ER-/PR-/HER-2+아형유선암적림상병이학특정상사,예후상방.
Objective To analyze the clinical pathologic features and prognosis of triple negative breast cancer. Method A total of 570 cases of breast cancer between January 2005 and June 2007 were analyzed,113 cases were negative for estrogen receptor(ER), progesterone receptor(PR) and HER-2 as the triple negative group, 48 cases were negative for ER, PR and positive for HER-2 as the control group. The clinical pathologic features, recurrence and survival of the patients were compared. Results The median age was 46 years old, 15 cases (13.3%) had a breast cancer family history or oophoroma family history,86.7%(98/113) of pathological types were invasive ductal carcinoma,lymph node metastases were detected in 31.0%(35/113 ) in the triple negative group. No significant difference was found for p53 staining between the triple negative group[58.4%(66/113)positive] and the control group [41.7%(20/48) positive] (P＞0.05).The median time of follow-up was 24 months,the loss was 5 cases, 10 cases (9.3%, 10/108) had local recurrence and metastasis,and 8 cases (7.4%,8/108) died from breast cancer metastases,2-year survival rate was 96.2% in the triple negative group.There was no significant difference in local recurrence and survival time between the triple negative group and the control group (P＞0.05). Conclusions The incidence of triple negative breast cancer is higher than other data reported. Triple negative breast cancer exhibits the same clinical pathological features compared with ER-/PR-/HER-2 + subtypes,and the prognosis is similar to the controls.
